Clinical Trials Logo

Filter by:
NCT ID: NCT05464628 Completed - Healthy Clinical Trials

Drug Interaction Study of ASC42 With Atorvastatin

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether ASC42 alters the pharmacokinetics of atorvastatin in healthy subjects.

NCT ID: NCT05464420 Completed - Clinical trials for Pneumococcal Disease

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Start date: August 12, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age. The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.

NCT ID: NCT05464069 Completed - Migraine Clinical Trials

Safety of Nerivio in Pregnant Women With Migraine

Start date: August 1, 2022
Phase:
Study type: Observational

This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica's user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is based on an e-Survey including an e-eligibility questionnaire, an e-ICF ande-Questionnaire. Participants will be compensated for their time.

NCT ID: NCT05463978 Completed - Clinical trials for Non-facial Skin Aesthetic Conditions

Sculptra Chart Review

Start date: July 14, 2022
Phase:
Study type: Observational

Multi-center retrospective chart review to evaluate the safety of Sculptra Aesthetic when used in non-facial areas

NCT ID: NCT05463822 Completed - Overactive Bladder Clinical Trials

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

FETOC
Start date: June 20, 2019
Phase: Early Phase 1
Study type: Interventional

Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope inserted into the bladder which can be painful and is associated with a risk of urinary tract infection. The purpose of this study is to determine if transvaginal injection of BTA into the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the treatment of refractory overactive bladder.

NCT ID: NCT05463770 Completed - Schizophrenia Clinical Trials

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Start date: August 30, 2022
Phase: Phase 1
Study type: Interventional

A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: - how the body processes (uses) glucose (blood sugar) - how much insulin the pancreas can make. Insulin is a hormone that lowers blood sugar levels in the body. The information from this study will help to understand any effect the study medication may have on how the body uses and stores glucose. This study is accepting both male and female subjects. It will be held in approximately 6 locations in the United States. Participation could last up to 12 weeks.

NCT ID: NCT05463744 Completed - Diabetes Clinical Trials

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

QWINT-5
Start date: August 12, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

NCT ID: NCT05463198 Completed - Fluid Loss Clinical Trials

Evaluation of Physiological Variables and Detection of Blood Loss Using the Zynex Fluid Monitoring System, Model CM-1600

Start date: September 14, 2022
Phase: N/A
Study type: Interventional

The study is a prospective, non-randomized, non-blinded, non-significant risk, multi-center study enrolling up to 500 healthy adult subjects consented to undergo a whole blood donation procedure. The study will involve enrolling subjects that will undergo blood donation wearing the study device (CM-1600 Device) and capture study-required physiological parameters pre-, during, and post-donation.

NCT ID: NCT05463068 Completed - COVID-19 Clinical Trials

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Start date: July 11, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.

NCT ID: NCT05463042 Completed - Clinical trials for Intermittent Hypoxia

Intermittent Hypoxia and Balance Control

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the effect of acute mild intermittent hypoxia on ankle plantarflexor muscle output during balance regulation and walking in younger and older adults. Fifteen younger adults and 15 older adults will be recruited to participate in the cross-over design study that requires 2 visits (at least 1-week apart). Participants will be pseudo-randomly assigned to receive either intermittent hypoxia or sham during the first visit, and then switch over to receive sham or intermittent hypoxia during the 2nd visit. Muscle activation patterns and kinetic and kinematics during standing and walking will be recorded before and after the intermittent hypoxia/sham. It is hypothesized that compared to the sham condition, both younger and older participants will show greater increases in ankle plantarflexor muscle activation during gait and balance assessments following intermittent hypoxia.